Latest Headlines
-
Unilabs And Ambry Sign Agreement To Enhance Genetic Testing Services For Biopharma Companies In Europe, Latin America And The Middle East
1/26/2023
Unilabs, a leading diagnostic services provider, and Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx, have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.
-
Roche Launches COVID-19 PCR Test To Detect The Fast Spreading XBB.1.5 Omicron Sub-Variant
1/26/2023
Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. The XBB.1.5 variant is prevalent in the United States and is quickly spreading to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment strategies. The test, VirSNiP SARS-CoV-2 Spike F486P, is for use on the LightCycler® 480 II and cobas® z 480.
-
VieCure And Labcorp Collaboration Will Improve Clinical Workflow, Increasing Patient Access To Genomic Testing
1/25/2023
VieCure today announced a new collaboration with Labcorp to provide clinicians greater access to precision oncology decision support.
-
Singleron Launches Single Cell eQTL Analysis As Part Of Their Sequencing Service
1/25/2023
Bioinformatic experts at Singleron Biotechnologies, a leader in single cell sequencing, have developed a new single cell eQTL analysis workflow that takes advantage of single cell RNA sequencing (scRNAseq) and whole genome sequencing (WGS) data to predict cell-type specific eQTLs.
-
Thermo Fisher Scientific Partners With AstraZeneca To Develop Solid Tissue And Blood-Based Companion Diagnostic Test For Tagrisso
1/24/2023
As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib).
-
Bionano Laboratories Expands Its Clinical Testing Menu With Launch Of Its First OGM-Based Laboratory Developed Test (LDT) For Hematological Malignancies
1/24/2023
Bionano Laboratories today announced the launch of OGM-Dx™ HemeOne™, a laboratory developed test (LDT) based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants (SVs) of diagnostic and prognostic utility in individuals with a new or an existing diagnosis of a hematological malignancy.
-
Geneseeq Receives CE Marks For MRD And MCED Tests
1/24/2023
Geneseeq Technology Inc. announced that Geneseeq's multi-cancer minimal residual disease detection (MRD) and multi-cancer early detection (MCED) kits were both CE Marked for liquid biopsy use in solid tumor patients.
-
Agilent To Collaborate With Quest Diagnostics To Extend Access To The Agilent Resolution ctDx FIRST Liquid Biopsy Test
1/23/2023
Agilent Technologies Inc. today announced an agreement with Quest Diagnostics, the world’s leading provider of diagnostic information services.
-
Foundation Medicine Announces Global Collaboration With Boehringer Ingelheim To Advance Biliary Tract Cancer Care
1/19/2023
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced a global collaboration with Boehringer Ingelheim to develop the company’s tissue-based comprehensive genomic profiling test, FoundationOneCDx, as a companion diagnostic for Boehringer Ingelheim’s investigational MDM2-p53 antagonist, BI 907828, in the United States, Japan and European Union.
-
Eurofins CellTx Opening Today At The University Of Arizona Tech Park
1/19/2023
Eurofins CellTx, an industry leader in regulated testing services for living donor eligibility testing, announced today the official opening of its new laboratory in Tucson, AZ.